Navigation Links
Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
Date:5/20/2013

WOBURN, Mass., May 20, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies.

Prior to joining Flexion, Mr. Driscoll was chief financial officer for Novavax (NASDAQ: NVAX) where he led a team that secured more than $250 million through a combination of investment funding and commercial and government contracts. He was also instrumental in increasing Novavax' institutional shareholder base, expanding analyst coverage and implementing numerous financial reforms that strengthened that company's position. Prior to Novavax, Mr. Driscoll served as chief financial officer and subsequently chief executive officer of publicly-traded Genelabs, chief financial officer of private company Astraris and chief executive officer of OXiGENE.

"We are delighted to add a leader of Fred's experience and expertise to our team as we continue to focus on increasing investor value while advancing our pipeline of sustained release, intra-articular osteoarthritis medicines," said Michael Clayman , M.D., chief executive officer of Flexion. "With Phase 2b data for our lead compound on the horizon, we are confident that Fred will play an important role in the future of the company."

Mr. Driscoll holds a bachelor's degree in accounting and finance from Bentley University in Waltham, Mass.

About Flexion TherapeuticsFlexion is a clinical-stage specialty pharmaceutical company developing innovative therapeutics for musculoskeletal disorders. In our efforts to provide products with superior efficacy and safety,
'/>"/>

SOURCE Flexion Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
6. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
7. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
8. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
9. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
10. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
11. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... (PRWEB) November 20, 2014 Offering a ... Sartorius Entris Balance promotion . The Sartorius Entris ... a durable, high accuracy, and easy-to-maintain balance entry level ... Germany. It was designed to help customer’s bridge the ... a balance that is very durable. Sartorius is the ...
(Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
Breaking Biology Technology:Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... DIEGO, May 24, 2012 Sangart, Inc., a global ... therapies for patients in acute ischemic crisis, today announced ... funding from existing investor, Leucadia National Corporation. This funding ... stock warrants previously held by Leucadia and brings the ...
... 23, 2012 Exosome Diagnostics, a leading developer ... personalized and non-invasive cancer diagnostics, today presented two ... sampling of patients, urine to detect and manage ... study, the presence of a prostate cancer-specific biomarker ...
... , WASHINGTON, May 23Whether used in telescopes or ... to avoid being overwhelmed by stray thermal radiation. ... the Chinese Academy of Sciences, and Duke University ... carbon nanotubes (SWNTs) to create highly sensitive, "uncooled" ...
Cached Biology Technology:Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock 2Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer 2Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer 3Sensing the infrared: Researchers improve IR detectors with single-walled carbon nanotubes 2Sensing the infrared: Researchers improve IR detectors with single-walled carbon nanotubes 3
(Date:11/4/2014)... amount of death at the right time might actually ... research that could help in understanding animal populations, pest ... a paper in the journal Trends in Ecology ... colleagues conclude that the kind of positive population effect ... or mortality, depends on the size and developmental stage ...
(Date:11/4/2014)... majority of Madagascar,s 101 species of lemurs are threatened ... the rainforests they call home. A new study by ... have on rainforest tree populations, which raises concerns about ... region,s rich biodiversity. , A large proportion of trees ... Lemurs in turn disperse the seeds of their fruit ...
(Date:11/3/2014)... report that low birth weight and preterm birth are ... in adulthood. Findings published in the American College of ... indicate that low birth weight and pre-term babies were ... OA as adults. , According to the ACR, ... diagnosed with clinical OA. Symptoms of OA range from ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Preterm, low birth-weight babies may need new hips in adulthood 2
... The future of high-intensity x-ray science has never ... Energy,s Argonne National Laboratory have devised a new type ... laser oscillator (X-FELO) we are proposing can create x-rays ... operating machines," Argonne Distinguished fellow Kwang-Je Kim said. ...
... in neural tissue engineering, has been awarded a prestigious ... Foundation (NSF). Pfister, who is an assistant ... Engineering, received the award to support and expand his ... regenerating damaged or diseased nerve cells. In collaboration ...
... UCLA cellular neuroscientists are providing new insights into the mechanisms ... treat long-term memory disorders. "The more ... brain and how our memories are maintained in the brain, ... long-term memory loss," said David Glanzman, UCLA professor of physiological ...
Cached Biology News:A novel X-ray source could be brightest in the world 2NJIT biomedical engineer receives NSF Career Development Award 2Study of marine snail leads to new insights into long-term memory 2Study of marine snail leads to new insights into long-term memory 3Study of marine snail leads to new insights into long-term memory 4
Peptide-affinity Purified Polyclonal Antibody to Prolactin Releasing Hormone Receptor (GPR10)...
Applications: Western blotting ...
Mitochondria/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
... the autofluorescent pigment lipofuscin accumulates in ... including neurons. The presence of lipofuscin ... fluorescence microscopy in the central nervous ... and emission spectra, which overlaps with ...
Biology Products: